Degenerative Arthropathy of Lumbar Spinal Facet JointNCT03304730
Prognostic Factors in Zygapophyseal Osteoarthritis Infiltration: a Prospective Cohort Study
An observational study of Degenerative Arthropathy of Lumbar Spinal Facet Joint, run by Hospital Israelita Albert Einstein at 1 site in Brazil.
Trial summary
Magnet Resonance Image findings of facet osteoarthritis and patient characteristics are prognostic factors for improving or worsening the clinical outcome after treatment with facet infiltration. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Degenerative Arthropathy of Lumbar Spinal Facet Joint
- How many people
- 147 participants
- Where
- 1 siteBrazil
- Study dates
- 1 Sep 2017to Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients seen at the spine outpatient clinic of a tertiary hospital with clinical diagnosis of low back pain of facet origin will be eligible to participate in the study
Who may be able to join
- The following are inclusion criteria for participants:
- Older than 18 years;
- Fluent or native Portuguese language speaker;
- Continuous or intermittent low back pain for at least three months;
- Low back pain with or without irradiation to the gluteal region indicating facet syndrome (pain is aggravated by spine extension or bending toward the affected side; pain is exacerbated by prolonged sitting or walking up steps, as well as retaining one position for a prolonged time);
- Failure of traditional treatment includes, but is not limited to, physical or drug therapy;
- Understand the purpose of the study;
- Voluntarily provide a free and informed consent form, by themselves or through their partners, and complete the questionnaires, before undergoing infiltration, over the telephone or online during the follow-up.
Who cannot join
- The following are exclusion criteria for participants:
- Younger than 18 years old,
- Symptomatic lumbar spinal stenosis with claudication or radiculopathy;
- Evidence of radiculopathy;
- Active rheumatologic diseases;
- Congenital or acquired deformities of the lumbar spine;
Show all 15Show fewer
- Fracture or sequel of lumbar spine fracture of traumatic, pathological or osteoporotic origin;
- Surgical manipulation of the lumbar spine;
- MRI scans of limited quality and incomplete sequences;
- Treated with systemic steroids less than one month before the IFI;
- Treated with IFI with steroids within the last six months;
- Diagnosed with uncontrolled diabetes mellitus;
- History of allergy to anesthetics or adverse reaction to steroids;
- Pregnant women or women who breastfed;
- Who could not be contacted over the phone during follow-up.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil1 site, 1 recruiting
- Recruiting
Hospital Israelista Albert Einstein
São Paulo, São Paulo, 05652-900
Joao C Rodrigues, MD, 551121512452, joao.rodrigues@einstein.br
Mario Lenza, PhD, 551121511444, mario.lenza@einstein.br
About this study
Official title: Prognostic Factors of Efficacy in Corticoid and Anesthetic Joint Infiltration for the Treatment of Patients With Low Back Pain Secondary to Zygapophyseal Osteoarthritis: a Prospective Cohort Study
Magnet Resonance Image findings of facet osteoarthritis and patient characteristics are prognostic factors for improving or worsening the clinical outcome after treatment with facet infiltration.
Read the detailed description
- Introduction: Low back pain is one of the significant health problems; studies have shown that it can affect 80-85% of people throughout life; consisting of the second major cause of work withdrawal. In the investigation by lumbar spine imaging methods, facet osteoarthritis (FO) is one of the most prevalent diagnoses, in 59.6% for men and 66.7% for women. The process of osteoarthritis begins early in the spine; more than half of adults are under 30 years old, presenting degenerative changes in the facets, being more commonly affected by the L4-L5 level. It is estimated that the pain of facet origin corresponds to 30% of cases of low back pain. The treatment of low back pain, which presents questionable results, has a substantial economic impact on the health system and represents a growing concern for public and medical policymakers. The lack of diagnostic accuracy and the various types of treatment without evidence of appropriate effectiveness are considered the leading causes of the increasing costs of the health system. Biomechanical, neuroanatomical, and neurophysiological studies demonstrated free and encapsulated nerve endings in the lumbar facet joints and nerves containing substance P and peptides related to the calcitonin gene. Chemical or mechanical stimuli can cause pain. The pathophysiology of facet pain is not fully understood, but it is believed that facet osteoarthritis is due to repetitive mechanical stress, with subsequent inflammation and elongation of the joint capsule, generating pain. Several treatments are used in low back pain secondary to FO. The most used are non-hormonal anti-inflammatory drugs and physiotherapy as a conservative measure. Interventional procedures such as facet intraarticular or periarticular infiltration of corticoid for neural blockade and denervation by radiofrequency are considered minimally invasive options, indicated for cases in which conservative treatment fails. Surgical treatment of arthrodesis is also part of the therapeutic options. A systemic corticosteroid is within the available therapeutic arsenal but has undesirable side effects, and its use is restricted in a short period. In order to increase drug concentration at the symptom site, without the undesirable side effects of the systemic corticosteroid, facet intraarticular infiltration (FI) has been used as a complementary treatment. The therapeutic value of FI is not consensus, with widely divergent results in the literature. Nevertheless, it is one of the most used treatments, observing a growing demand for this procedure in the last decades. The selection of the appropriate patient, who would benefit from the treatment, is a determining factor in the outcome of the FI since, in the thesis, only the subgroup of patients with the active inflammatory process in the facet joint would have a positive result corticosteroid infiltration. Identifying this subgroup of patients is a challenge because the diagnosis of facet origin pain is often imprecise. With proper and accurate diagnosis, FI is expected to achieve better results. Magnetic resonance imaging (MRI) can identify the morphological characteristics of facet osteoarthritis, generating a classification in degrees mild, moderate, or severe. It also allows diagnosing the presence or absence of an inflammatory process in the facet joint, usually manifested by indirect signs such as bone edema, periarticular soft-tissue edema, joint effusion, and synovitis. However, morphological characteristics and inflammatory markers of MR imaging have not been tested as prognostic factors of FI efficacy. Patients' characteristics such as gender, age, schooling, family income, smoking, body mass index, professional activity may affect the expected results, but they have not been tested as prognostic factors of FI efficacy. 1.1 Rationale: The relationship between MRI findings of facet osteoarthritis and the effect on FI of corticoid and anesthetic has not been studied. The relationship between the characteristics of age, sex, education, family income, smoking, body mass index, professional activity, and the effect on FI of steroids and anesthetics has not been studied. Determining the prognostic factors may impact the clinical routine of physicians and patients, guiding the treatment, and selecting those with chances of better results with the FI. 1.2 Hypotheses: MRI findings of facet osteoarthritis and patient characteristics are prognostic factors for improving or worsening the clinical outcome after treatment with FI.
- Purpose: To determine the prognostic factors of corticoid and anesthetic infiltration in treating facet osteoarthritis in the lumbar spine. To determine the association between MRI imaging findings and pain, functional disability, and patient's quality of life. To determine the association between age, sex, schooling, family income, smoking, body mass index, professional activity in pain, functional disability, and patient's quality of life.
- Method: This prospective cohort study will include all patients with clinical suspicion of facet pain who have undergone MRI and have been referred to the intervention center of the image department of a tertiary hospital to perform FI with corticoid and anesthetic. On the day of the procedure, patients will be invited to participate in the study. Before performing the facet infiltration, patients will respond to an informed consent form (ICF) and five questionnaires: 1. data collection form; 2. the visual analogue pain scale (VAS); 3. Roland-Morris questionnaire on functional disability; 4. Oswestry questionnaire on functional disability; 5. EuroQol questionnaire (EQ-5D) on quality of life. All patients will be followed for one year, responding by telephone VAS, Roland-Morris, Oswestry, and EQ-5D questionnaires at 1, 3, 6, and 12 months after the FI to measure the effectiveness of the proposed treatment. The systemic use of corticosteroids, the performance of another infiltration or surgery, and the number of analgesics ingested per day will also be evaluated in the follow-up. Researchers will only apply the specific questionnaires of the project, not influence the indication, accomplishment, and treatment of FI complications or the clinical routine of the intervention center. The following variables will be collected to characterize the sample: age (years), sex (male or female), schooling (years of study), smoking (number of cigarettes per day), family income, professional activity (type of occupation, number of hours sitting or standing, carrying weight or not) and oral analgesic use (number of tablets taken per day). The FI procedure will be guided by computed tomography. The radiation dose used will be the minimum possible to obtain images with sufficient quality to guide the location and progression of the needle, being within limits established in the institutional protocols and already practiced in the department. After imaging confirmation of the correct intraarticular positioning of the needle, a solution containing triamcinolone 20 mg/ml and hydrochloride of naropin in a ratio of 1: 1, in the volume of 1.5 to 2.0 ml, will be injected. After the procedure, the patient will be discharged and advised to do home rest for 24 hours. The study design proposes to determine the correlation between the clinical outcome measured by the results of the VAS, Roland-Morris, Oswestry, and EQ-5D questionnaires, and the variables identified by MRI and also the correlation between the clinical outcome and the variables: age, sex, educational level, smoking, family income, body mass index (BMI), professional activity and amount of analgesics ingested per day. All patients will be followed for one year, responding by telephone VAS, Roland-Morris, Oswestry, and EQ-5D questionnaires at 1, 3, 6, and 12 months after the IF to measure the effectiveness of the proposed treatment. The systemic use of corticosteroids, the performance of another infiltration or surgery, and the number of analgesics ingested per day will also be evaluated.
3.1 Image exams and evaluator: All the lumbar spine MRI scans performed by the patients will be analyzed. Two radiologists will read MRI exams without knowledge of clinical, laboratory, or patient evaluation and questionnaire results. The variables degree of facet osteoarthritis, bone edema, periarticular edema, synovitis, effusion, osteophytes, subchondral sclerosis, subchondral cysts, sliding, sagittal or horizontal orientation, identified by MRI, will be tabulated.
3.2 Rating: MRI studies will be evaluated respecting patients' anonymity. Patients' characteristics, MRI imaging findings, and VAS, Roland-Morris, Oswestry, and EQ-5D questionnaires will be tabulated according to the following characteristics: age, sex, schooling, family income, smoking, weight, height, body mass index (BMI), occupational activity, analgesic ingestion, laterality, location, degree of facet arthritis, bone edema, periarticular edema, synovitis, effusion, osteophytes, subchondral sclerosis, subchondral cysts, orientation sagittal or horizontal, facet sliding, VAS, Roland-Morris, EQ-5D, and Oswestry.
3.3 Sample size estimation: Taking into account the primary variable of the study as the presence of inflammatory process in the facet joint, identified at MRI, with an expected prevalence of 30% in the sample and as the primary outcome the functional disability, as measured by the Roland-Morris questionnaire, when checking the sample size needed to detect a difference between the groups, with and without inflammatory process, before and after the FI procedure, it will require 117 patients in total, with a difference in the mean of the groups of 4.0 points. This calculation considered that the standard deviation of the difference of averages between the groups would be homogeneous and 7.0 points, as observed in the literature. Therefore, this study will include 147 patients considering a loss of follow-up in 20%. The sample size needed to compare the groups will be recalculated once the study has a three-month follow-up of 70 patients based on the SD and the proportion of facet inflammation observed. The calculations were made considering 80% test power and a significance level of 5%.
3.4 Statistical analysis: Patient characteristics, MRI findings and pain (VAS), disability (Roland Morris and Oswestry), quality of life (EQ-5D) scores will be described using absolute frequencies and percentages in categorical variables, or through means, standard deviations or medians and quartiles, in addition to minimum and maximum values, in quantitative variables. The MRI characteristics analyzed by two observers will be evaluated for agreement using correlation coefficients appropriate to the observed distribution of cases, such as the Kappa coefficient. To evaluate MRI findings and patient characteristics (age, sex, smoking, family income, BMI, education, occupation, and analgesic intake) in the evolution of pain (VAS), disability (Roland Morris and Oswestry), and quality of life (EuroQol) during twelve months after infiltration, will be used mixed linear models or generalized linear models, in multiple approaches, being such models appropriate for measurements obtained from the same patient at different times. The results of the models will be presented by effect estimates (change in mean pain or means of functional disability and quality of life) and 95% confidence intervals.
We plan to carry out the analysis with the statistical package R and consider the significance level 5%.
- Keywords
- Zygapophyseal Joint, Low Back Pain, Spine Osteoarthritis
- Medical subject headings
- Low Back Pain, Osteoarthritis, Spine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| facet inflammatory signs | patients with facet inflammatory signs identified on MRI | |
| no facet inflammatory signs | patients without facet inflammatory signs identified on MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Roland Moris Questionnaire
functional disability
Measured: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Secondary outcomes (4)
Change in Visual Analogue Pain Scale (VAS)
pain
Measured: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Change in Oswestry Back Pain Disability
functional disability
Measured: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Change in EuroQol questionnaire (EQ-5D)
quality of life
Measured: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Reduction in pain medication usage
indirect sign of improvement or worsening of pain
Measured: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2017
- Study start1 Sep 2017
- Primary completionDec 2028 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (25)Papers the sponsor has linked to this study.
- Other trials for Degenerative Arthropathy of Lumbar Spinal Facet JointStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 147 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Israelita Albert Einstein
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joao Carlos Rodrigues, Hospital Israelita Albert Einstein
- Investigators
- Joao C Rodrigues, MD, Principal investigator, Hospital Israelita Albert Einstein
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03304730
- Sponsor's protocol ID
- 65291417.0.0000.0071
- Status last verified
- Oct 2026
- First submitted
- 26 Sep 2017
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Eubanks JD, Lee MJ, Cassinelli E, Ahn NU. Prevalence of lumbar facet arthrosis and its relationship to age, sex, and race: an anatomic study of cadaveric specimens. Spine (Phila Pa 1976). 2007 Sep 1;32(19):2058-62. doi: 10.1097/BRS.0b013e318145a3a9.
PubMed 17762805DePalma MJ, Ketchum JM, Saullo T. What is the source of chronic low back pain and does age play a role? Pain Med. 2011 Feb;12(2):224-33. doi: 10.1111/j.1526-4637.2010.01045.x. Epub 2011 Jan 25.
PubMed 21266006Manchikanti L, Pampati V, Falco FJ, Hirsch JA. An updated assessment of utilization of interventional pain management techniques in the Medicare population: 2000 - 2013. Pain Physician. 2015 Mar-Apr;18(2):E115-27.
PubMed 25794210VIRKKUNEN M, LEHTINEN L. Side effects of corticosteroids observations after five years' continuous use. Acta Med Scand Suppl. 1958;341:205-10. doi: 10.1111/j.0954-6820.1958.tb19111.x. No abstract available.
PubMed 13605648KENDALL PH. THE SIDE-EFFECTS OF CORTICOSTEROIDS. Ann Phys Med. 1964 Aug;8:253-7. doi: 10.1093/rheumatology/7.7.253. No abstract available.
PubMed 14209712Lilius G, Laasonen EM, Myllynen P, Harilainen A, Gronlund G. Lumbar facet joint syndrome. A randomised clinical trial. J Bone Joint Surg Br. 1989 Aug;71(4):681-4. doi: 10.1302/0301-620X.71B4.2527856.
PubMed 2527856Ribeiro LH, Furtado RN, Konai MS, Andreo AB, Rosenfeld A, Natour J. Effect of facet joint injection versus systemic steroids in low back pain: a randomized controlled trial. Spine (Phila Pa 1976). 2013 Nov 1;38(23):1995-2002. doi: 10.1097/BRS.0b013e3182a76df1.
PubMed 23921331Falco FJ, Manchikanti L, Datta S, Sehgal N, Geffert S, Onyewu O, Zhu J, Coubarous S, Hameed M, Ward SP, Sharma M, Hameed H, Singh V, Boswell MV. An update of the effectiveness of therapeutic lumbar facet joint interventions. Pain Physician. 2012 Nov-Dec;15(6):E909-53.
PubMed 23159980Legiehn GM, Heran MK. Classification, diagnosis, and interventional radiologic management of vascular malformations. Orthop Clin North Am. 2006 Jul;37(3):435-74, vii-viii. doi: 10.1016/j.ocl.2006.04.005.
PubMed 16846771Hancock MJ, Maher CG, Latimer J, Spindler MF, McAuley JH, Laslett M, Bogduk N. Systematic review of tests to identify the disc, SIJ or facet joint as the source of low back pain. Eur Spine J. 2007 Oct;16(10):1539-50. doi: 10.1007/s00586-007-0391-1. Epub 2007 Jun 14.
PubMed 17566796WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser. 2003;919:i-x, 1-218, back cover.
PubMed 14679827Kalichman L, Li L, Kim DH, Guermazi A, Berkin V, O'Donnell CJ, Hoffmann U, Cole R, Hunter DJ. Facet joint osteoarthritis and low back pain in the community-based population. Spine (Phila Pa 1976). 2008 Nov 1;33(23):2560-5. doi: 10.1097/BRS.0b013e318184ef95.
PubMed 18923337Beaman DN, Graziano GP, Glover RA, Wojtys EM, Chang V. Substance P innervation of lumbar spine facet joints. Spine (Phila Pa 1976). 1993 Jun 15;18(8):1044-9. doi: 10.1097/00007632-199306150-00014.
PubMed 7690159van Kleef M, Vanelderen P, Cohen SP, Lataster A, Van Zundert J, Mekhail N. 12. Pain originating from the lumbar facet joints. Pain Pract. 2010 Sep-Oct;10(5):459-69. doi: 10.1111/j.1533-2500.2010.00393.x.
PubMed 20667027Deyo RA. Fusion surgery for lumbar degenerative disc disease: still more questions than answers. Spine J. 2015 Feb 1;15(2):272-4. doi: 10.1016/j.spinee.2014.11.004.
PubMed 25598279
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Factors of Efficacy in Corticoid and Anesthetic Joint Infiltration for the Treatment of Patients With Low Back Pain Secondary to Zygapophyseal Osteoarthritis: a Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT03304730
- Acronym / sponsor ID
- 65291417.0.0000.0071
- Keywords
- Zygapophyseal Joint, Low Back Pain, Spine Osteoarthritis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 147 participants (estimated)
- Lead sponsor
- Hospital Israelita Albert EinsteinUniversity, hospital or other
- Study start
- 1 Sep 2017 (actual)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 9 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Magnet Resonance Image findings of facet osteoarthritis and patient characteristics are prognostic factors for improving or worsening the clinical outcome after treatment with facet infiltration.
Detailed description
- Introduction: Low back pain is one of the significant health problems; studies have shown that it can affect 80-85% of people throughout life; consisting of the second major cause of work withdrawal. In the investigation by lumbar spine imaging methods, facet osteoarthritis (FO) is one of the most prevalent diagnoses, in 59.6% for men and 66.7% for women. The process of osteoarthritis begins early in the spine; more than half of adults are under 30 years old, presenting degenerative changes in the facets, being more commonly affected by the L4-L5 level. It is estimated that the pain of facet origin corresponds to 30% of cases of low back pain. The treatment of low back pain, which presents questionable results, has a substantial economic impact on the health system and represents a growing concern for public and medical policymakers. The lack of diagnostic accuracy and the various types of treatment without evidence of appropriate effectiveness are considered the leading causes of the increasing costs of the health system. Biomechanical, neuroanatomical, and neurophysiological studies demonstrated free and encapsulated nerve endings in the lumbar facet joints and nerves containing substance P and peptides related to the calcitonin gene. Chemical or mechanical stimuli can cause pain. The pathophysiology of facet pain is not fully understood, but it is believed that facet osteoarthritis is due to repetitive mechanical stress, with subsequent inflammation and elongation of the joint capsule, generating pain. Several treatments are used in low back pain secondary to FO. The most used are non-hormonal anti-inflammatory drugs and physiotherapy as a conservative measure. Interventional procedures such as facet intraarticular or periarticular infiltration of corticoid for neural blockade and denervation by radiofrequency are considered minimally invasive options, indicated for cases in which conservative treatment fails. Surgical treatment of arthrodesis is also part of the therapeutic options. A systemic corticosteroid is within the available therapeutic arsenal but has undesirable side effects, and its use is restricted in a short period. In order to increase drug concentration at the symptom site, without the undesirable side effects of the systemic corticosteroid, facet intraarticular infiltration (FI) has been used as a complementary treatment. The therapeutic value of FI is not consensus, with widely divergent results in the literature. Nevertheless, it is one of the most used treatments, observing a growing demand for this procedure in the last decades. The selection of the appropriate patient, who would benefit from the treatment, is a determining factor in the outcome of the FI since, in the thesis, only the subgroup of patients with the active inflammatory process in the facet joint would have a positive result corticosteroid infiltration. Identifying this subgroup of patients is a challenge because the diagnosis of facet origin pain is often imprecise. With proper and accurate diagnosis, FI is expected to achieve better results. Magnetic resonance imaging (MRI) can identify the morphological characteristics of facet osteoarthritis, generating a classification in degrees mild, moderate, or severe. It also allows diagnosing the presence or absence of an inflammatory process in the facet joint, usually manifested by indirect signs such as bone edema, periarticular soft-tissue edema, joint effusion, and synovitis. However, morphological characteristics and inflammatory markers of MR imaging have not been tested as prognostic factors of FI efficacy. Patients' characteristics such as gender, age, schooling, family income, smoking, body mass index, professional activity may affect the expected results, but they have not been tested as prognostic factors of FI efficacy. 1.1 Rationale: The relationship between MRI findings of facet osteoarthritis and the effect on FI of corticoid and anesthetic has not been studied. The relationship between the characteristics of age, sex, education, family income, smoking, body mass index, professional activity, and the effect on FI of steroids and anesthetics has not been studied. Determining the prognostic factors may impact the clinical routine of physicians and patients, guiding the treatment, and selecting those with chances of better results with the FI. 1.2 Hypotheses: MRI findings of facet osteoarthritis and patient characteristics are prognostic factors for improving or worsening the clinical outcome after treatment with FI.
- Purpose: To determine the prognostic factors of corticoid and anesthetic infiltration in treating facet osteoarthritis in the lumbar spine. To determine the association between MRI imaging findings and pain, functional disability, and patient's quality of life. To determine the association between age, sex, schooling, family income, smoking, body mass index, professional activity in pain, functional disability, and patient's quality of life.
- Method: This prospective cohort study will include all patients with clinical suspicion of facet pain who have undergone MRI and have been referred to the intervention center of the image department of a tertiary hospital to perform FI with corticoid and anesthetic. On the day of the procedure, patients will be invited to participate in the study. Before performing the facet infiltration, patients will respond to an informed consent form (ICF) and five questionnaires: 1. data collection form; 2. the visual analogue pain scale (VAS); 3. Roland-Morris questionnaire on functional disability; 4. Oswestry questionnaire on functional disability; 5. EuroQol questionnaire (EQ-5D) on quality of life. All patients will be followed for one year, responding by telephone VAS, Roland-Morris, Oswestry, and EQ-5D questionnaires at 1, 3, 6, and 12 months after the FI to measure the effectiveness of the proposed treatment. The systemic use of corticosteroids, the performance of another infiltration or surgery, and the number of analgesics ingested per day will also be evaluated in the follow-up. Researchers will only apply the specific questionnaires of the project, not influence the indication, accomplishment, and treatment of FI complications or the clinical routine of the intervention center. The following variables will be collected to characterize the sample: age (years), sex (male or female), schooling (years of study), smoking (number of cigarettes per day), family income, professional activity (type of occupation, number of hours sitting or standing, carrying weight or not) and oral analgesic use (number of tablets taken per day). The FI procedure will be guided by computed tomography. The radiation dose used will be the minimum possible to obtain images with sufficient quality to guide the location and progression of the needle, being within limits established in the institutional protocols and already practiced in the department. After imaging confirmation of the correct intraarticular positioning of the needle, a solution containing triamcinolone 20 mg/ml and hydrochloride of naropin in a ratio of 1: 1, in the volume of 1.5 to 2.0 ml, will be injected. After the procedure, the patient will be discharged and advised to do home rest for 24 hours. The study design proposes to determine the correlation between the clinical outcome measured by the results of the VAS, Roland-Morris, Oswestry, and EQ-5D questionnaires, and the variables identified by MRI and also the correlation between the clinical outcome and the variables: age, sex, educational level, smoking, family income, body mass index (BMI), professional activity and amount of analgesics ingested per day. All patients will be followed for one year, responding by telephone VAS, Roland-Morris, Oswestry, and EQ-5D questionnaires at 1, 3, 6, and 12 months after the IF to measure the effectiveness of the proposed treatment. The systemic use of corticosteroids, the performance of another infiltration or surgery, and the number of analgesics ingested per day will also be evaluated.
3.1 Image exams and evaluator: All the lumbar spine MRI scans performed by the patients will be analyzed. Two radiologists will read MRI exams without knowledge of clinical, laboratory, or patient evaluation and questionnaire results. The variables degree of facet osteoarthritis, bone edema, periarticular edema, synovitis, effusion, osteophytes, subchondral sclerosis, subchondral cysts, sliding, sagittal or horizontal orientation, identified by MRI, will be tabulated.
3.2 Rating: MRI studies will be evaluated respecting patients' anonymity. Patients' characteristics, MRI imaging findings, and VAS, Roland-Morris, Oswestry, and EQ-5D questionnaires will be tabulated according to the following characteristics: age, sex, schooling, family income, smoking, weight, height, body mass index (BMI), occupational activity, analgesic ingestion, laterality, location, degree of facet arthritis, bone edema, periarticular edema, synovitis, effusion, osteophytes, subchondral sclerosis, subchondral cysts, orientation sagittal or horizontal, facet sliding, VAS, Roland-Morris, EQ-5D, and Oswestry.
3.3 Sample size estimation: Taking into account the primary variable of the study as the presence of inflammatory process in the facet joint, identified at MRI, with an expected prevalence of 30% in the sample and as the primary outcome the functional disability, as measured by the Roland-Morris questionnaire, when checking the sample size needed to detect a difference between the groups, with and without inflammatory process, before and after the FI procedure, it will require 117 patients in total, with a difference in the mean of the groups of 4.0 points. This calculation considered that the standard deviation of the difference of averages between the groups would be homogeneous and 7.0 points, as observed in the literature. Therefore, this study will include 147 patients considering a loss of follow-up in 20%. The sample size needed to compare the groups will be recalculated once the study has a three-month follow-up of 70 patients based on the SD and the proportion of facet inflammation observed. The calculations were made considering 80% test power and a significance level of 5%.
3.4 Statistical analysis: Patient characteristics, MRI findings and pain (VAS), disability (Roland Morris and Oswestry), quality of life (EQ-5D) scores will be described using absolute frequencies and percentages in categorical variables, or through means, standard deviations or medians and quartiles, in addition to minimum and maximum values, in quantitative variables. The MRI characteristics analyzed by two observers will be evaluated for agreement using correlation coefficients appropriate to the observed distribution of cases, such as the Kappa coefficient. To evaluate MRI findings and patient characteristics (age, sex, smoking, family income, BMI, education, occupation, and analgesic intake) in the evolution of pain (VAS), disability (Roland Morris and Oswestry), and quality of life (EuroQol) during twelve months after infiltration, will be used mixed linear models or generalized linear models, in multiple approaches, being such models appropriate for measurements obtained from the same patient at different times. The results of the models will be presented by effect estimates (change in mean pain or means of functional disability and quality of life) and 95% confidence intervals.
We plan to carry out the analysis with the statistical package R and consider the significance level 5%.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| facet inflammatory signs | – | –patients with facet inflammatory signs identified on MRI |
| no facet inflammatory signs | – | –patients without facet inflammatory signs identified on MRI |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients seen at the spine outpatient clinic of a tertiary hospital with clinical diagnosis of low back pain of facet origin will be eligible to participate in the study
Key inclusion criteria (8 listed)
- Older than 18 years;
- Fluent or native Portuguese language speaker;
- Continuous or intermittent low back pain for at least three months;
- Low back pain with or without irradiation to the gluteal region indicating facet syndrome (pain is aggravated by spine extension or bending toward the affected side; pain is exacerbated by prolonged sitting or walking up steps, as well as retaining one position for a prolonged time);
- Failure of traditional treatment includes, but is not limited to, physical or drug therapy;
Key exclusion criteria (15 listed)
- Younger than 18 years old,
- Symptomatic lumbar spinal stenosis with claudication or radiculopathy;
- Evidence of radiculopathy;
- Active rheumatologic diseases;
- Congenital or acquired deformities of the lumbar spine;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in Roland Moris Questionnaire
Time frame: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
functional disability
4 secondary outcomes
Change in Visual Analogue Pain Scale (VAS)
Time frame: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Change in Oswestry Back Pain Disability
Time frame: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Change in EuroQol questionnaire (EQ-5D)
Time frame: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Reduction in pain medication usage
Time frame: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Background: PubMed 17762805Eubanks JD, Lee MJ, Cassinelli E, Ahn NU. Prevalence of lumbar facet arthrosis and its relationship to age, sex, and race: an anatomic study of cadaveric specimens. Spine (Phila Pa 1976). 2007 Sep 1;32(19):2058-62. doi: 10.1097/BRS.0b013e318145a3a9.
- Background: PubMed 21266006DePalma MJ, Ketchum JM, Saullo T. What is the source of chronic low back pain and does age play a role? Pain Med. 2011 Feb;12(2):224-33. doi: 10.1111/j.1526-4637.2010.01045.x. Epub 2011 Jan 25.
- Background: PubMed 25794210Manchikanti L, Pampati V, Falco FJ, Hirsch JA. An updated assessment of utilization of interventional pain management techniques in the Medicare population: 2000 - 2013. Pain Physician. 2015 Mar-Apr;18(2):E115-27.
- Background: PubMed 13605648VIRKKUNEN M, LEHTINEN L. Side effects of corticosteroids observations after five years' continuous use. Acta Med Scand Suppl. 1958;341:205-10. doi: 10.1111/j.0954-6820.1958.tb19111.x. No abstract available.
- Background: PubMed 14209712KENDALL PH. THE SIDE-EFFECTS OF CORTICOSTEROIDS. Ann Phys Med. 1964 Aug;8:253-7. doi: 10.1093/rheumatology/7.7.253. No abstract available.
- Background: PubMed 2527856Lilius G, Laasonen EM, Myllynen P, Harilainen A, Gronlund G. Lumbar facet joint syndrome. A randomised clinical trial. J Bone Joint Surg Br. 1989 Aug;71(4):681-4. doi: 10.1302/0301-620X.71B4.2527856.
- Background: PubMed 23921331Ribeiro LH, Furtado RN, Konai MS, Andreo AB, Rosenfeld A, Natour J. Effect of facet joint injection versus systemic steroids in low back pain: a randomized controlled trial. Spine (Phila Pa 1976). 2013 Nov 1;38(23):1995-2002. doi: 10.1097/BRS.0b013e3182a76df1.
- Background: PubMed 23159980Falco FJ, Manchikanti L, Datta S, Sehgal N, Geffert S, Onyewu O, Zhu J, Coubarous S, Hameed M, Ward SP, Sharma M, Hameed H, Singh V, Boswell MV. An update of the effectiveness of therapeutic lumbar facet joint interventions. Pain Physician. 2012 Nov-Dec;15(6):E909-53.
- Background: PubMed 16846771Legiehn GM, Heran MK. Classification, diagnosis, and interventional radiologic management of vascular malformations. Orthop Clin North Am. 2006 Jul;37(3):435-74, vii-viii. doi: 10.1016/j.ocl.2006.04.005.
- Background: PubMed 17566796Hancock MJ, Maher CG, Latimer J, Spindler MF, McAuley JH, Laslett M, Bogduk N. Systematic review of tests to identify the disc, SIJ or facet joint as the source of low back pain. Eur Spine J. 2007 Oct;16(10):1539-50. doi: 10.1007/s00586-007-0391-1. Epub 2007 Jun 14.
- Background: PubMed 14679827WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser. 2003;919:i-x, 1-218, back cover.
- Background: PubMed 18923337Kalichman L, Li L, Kim DH, Guermazi A, Berkin V, O'Donnell CJ, Hoffmann U, Cole R, Hunter DJ. Facet joint osteoarthritis and low back pain in the community-based population. Spine (Phila Pa 1976). 2008 Nov 1;33(23):2560-5. doi: 10.1097/BRS.0b013e318184ef95.
- Individual participant dataSharing planned: No
Related trials for Degenerative Arthropathy of Lumbar Spinal Facet Joint
Recruiting
Mid- or High-flex Rods Versus Low-flex Rods of SpineShape System IV for Treatment of Degenerative Lumbar Spine Diseases
Degenerative Lumbar Spinal Stenosis, Facet Joint Arthrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joao C Rodrigues, MD principal investigator
Hospital Israelita Albert Einstein
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Degenerative Arthropathy of Lumbar Spinal Facet Joint, run by Hospital Israelita Albert Einstein at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joao C Rodrigues, MD (551121512452, joao.rodrigues@einstein.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Roland Moris Questionnaire (time frame: Change from baseline to 1 month, to 3 months, to 6 months, and to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03304730, which also lists 25 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.